Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target

HER2 is a known therapeutic target for about 30% of breast cancer patients where HER2 is over expressed and this is referred to as HER2 positive breast cancer. This subtype is characterized by a clinical behavior know to be especially aggressive. Improved HER2 targeting agents such as trastuzumab, p...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Bioinformation
Main Authors: Arannilewa1, Abiodun Julius, Suleiman Alakanse, Oluwaseun, Adesola, Adesola Oluwaseun, Israel Malachi, Oluwaseyi, Michael Obaidu, Ifedayo, Oluwafemi, Emmanuel Ekun, Damilola Afolayan, Emmanuel, Folakemi Afere, Patricia, Abdullateef Ayuba, Kayode, Oluwafemi Bolarinwa, Tolulope, Oche Ambrose, George
Formato: Artigo
Idioma:Inglês
Publicado: Biomedical Informatics 2018
Assuntos:
Hypothesis
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6563659/
https://ncbi.nlm.nih.gov/pubmed/31223207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6026/97320630014482
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares